Novo Nordisk AS (OCSE:NOVO B)
kr 775.8 18.5 (2.44%) Market Cap: 3.45 Til Enterprise Value: 3.43 Til PE Ratio: 36.59 PB Ratio: 28.65 GF Score: 97/100

Q4 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) Transcript

Feb 05, 2021 / 11:00AM GMT
Release Date Price: kr220.2 (-0.96%)
Operator

Hello, and welcome to the Q4 2020 Novo Nordisk A/S Earnings Presentation. (Operator Instructions) Today, I'm pleased to present Lars Fruergaard Jorgensen, CEO. Please go ahead with your meeting.

Lars Fruergaard Jorgensen;S;President
Novo Nordisk A;CEO & Member of Management Board

/- -

Thank you very much, and thank you to Bernstein for hosting us today. I'm Lars Fruergaard Jorgensen, the CEO of Novo Nordisk. And with me, I have Chief Financial Officer, Karsten Munk Knudsen; and Chief Science Officer, Mads Krogsgaard Thomsen.

We'll do a very quick opening review of a few slides, and then we'll go over to your questions. The first slide is our forward-looking statements.

I have to remind you that we will be talking about the future today, which obviously involves risks and uncertainties, and results could turn out to be different from what we preach here today.

If you look at our strategic aspiration for 2025, we're very pleased with the progress we have made during the full year of 2020 on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot